Sanofi (SNY)

43.71
0.09 0.21
NASDAQ : Health Technology
Prev Close 43.80
Open 44.21
Day Low/High 43.06 / 44.23
52 Wk Low/High 40.00 / 45.62
Volume 2.05M
Avg Volume 1.40M
Exchange NASDAQ
Shares Outstanding 2.49B
Market Cap 110.18B
EPS 2.00
P/E Ratio 23.54
Div & Yield 1.16 (2.65%)

Latest News

Sanofi Delivered Solid Growth In Q2 2019

Sanofi Delivered Solid Growth In Q2 2019

PARIS , July 29, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q2 2019 Change Change at CER H1 2019 Change Change at CER IFRS net sales reported €8,628m +5.

Busy Earnings Week, China Trade, Fed Moves, Trading Beyond Meat: Market Recon

Busy Earnings Week, China Trade, Fed Moves, Trading Beyond Meat: Market Recon

The real threat here would be if the Fed were fooled by domestic economic data that remains better than bad, from properly preparing for a very uncertain future.

Alphabet Shares Soar After Excellent Earnings Results

Alphabet Shares Soar After Excellent Earnings Results

A big jump in the market cap of Google's parent is in store thanks to an impressive second-quarter report.

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: SID, SNY Downgrades: EEI, NTP, PLAY Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

UniQure Jumps on Report It's Exploring a Possible Sale

UniQure Jumps on Report It's Exploring a Possible Sale

A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

Sanofi Oncology Pipeline Targeting Various Cancers Highlighted At ASCO 2019

Sanofi Oncology Pipeline Targeting Various Cancers Highlighted At ASCO 2019

- Pivotal Phase 3 data evaluated isatuximab (anti-CD38) in combination with pomalidomide/dexamethasone in prolonging progression-free survival in relapsed/refractory multiple myeloma

Sanofi Recognized By DiversityInc As A Top 50 Company

Sanofi Recognized By DiversityInc As A Top 50 Company

BRIDGEWATER, N.J.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Sanofi Named One Of America's Best Employers By Forbes

Sanofi Named One Of America's Best Employers By Forbes

BRIDGEWATER, N.J.

World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across The Globe

World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across The Globe

-- Nearly 17,000 patients in 40 developing countries have received treatment since donations began in 2015

Health Canada Issues Notice Of Compliance With Conditions (NOC/c) For LibtayoTM (cemiplimab), The First And Only Biologic For The Treatment Of Advanced Cutaneous Squamous Cell Carcinoma (CSCC)

Health Canada Issues Notice Of Compliance With Conditions (NOC/c) For LibtayoTM (cemiplimab), The First And Only Biologic For The Treatment Of Advanced Cutaneous Squamous Cell Carcinoma (CSCC)

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) * CSCC is the second most common skin cancer in Canada i TORONTO, April 11, 2019 /CNW Telbec/ - Sanofi Genzyme, the Specialty Care Business Unit of sanofi-aventis Canda Inc, announced today that Health Canada has...

Sanofi Provides Unprecedented Access To Its Insulins For One Set Monthly Price

Sanofi Provides Unprecedented Access To Its Insulins For One Set Monthly Price

* Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program

A Cereal Titan, a Jewelry Chain and Other Stocks That Look Good Short

SNY, RYN, I, SIG and K all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DHX, EWBC, KE, MSON, OMN, RDWR, RNR, SEE Downgrades: AR, FTAI, K, RYN, SNY, TWO, VNDA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

JPMorgan and Oracle Jump After Warren Buffett Buys Shares

JPMorgan and Oracle Jump After Warren Buffett Buys Shares

Warren Buffett's big buys of Oracle and JPMorgan have those stocks jumping Thursday.

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Nvidia, nvidia, NVIDIA. In non-Nvidia news, the market faces some serious threats in the back half of 2018. And hey, about Elon Musk's latest interview ...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CFBK, CLDT, SNY, VET Downgrades: ADNT, AOI, BVN Initiations: AMMA Read on to get TheStreet Quant Ratings' detailed report:

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.

Sanofi, Merck and J&J Tout Lower Drug Prices

Sanofi, Merck and J&J Tout Lower Drug Prices

While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed near session highs Monday.

TheStreet Quant Rating: B (Buy)